JP Morgan Chase’s iBio IBIO Stock Holding History

JP Morgan Chase’s Portfolio IBIO Stock Details IBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q4	–	Sell	-111	Closed	-$116K	–	5759
2020 Q3	$116K	Buy	+111	New	+$161K	﹤0.01%	4623

Other funds holding IBIO

AAA

Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return

FLSM

Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

LGM

Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return

Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

SCM

Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return

JP Morgan Chase's IBIO Position: Q1 2026 in Review

JP Morgan Chase held its iBio (IBIO) position steady in Q1 2026 at 2 shares worth $3. The position accounts for ﹤0.01% of the portfolio, ranked #7466.

JP Morgan Chase first reported a position in IBIO in Q2 2020 and has held it in 24 quarters since. The position peaked at $909K in Q1 2021. 52 funds tracked by Wall St. Rank hold IBIO as of Q1 2026.

JP Morgan Chase held 2 shares of iBio worth $3 as of Q1 2026.
JP Morgan Chase left its iBio share count unchanged in Q1 2026.
iBio made up ﹤0.01% of JP Morgan Chase's portfolio in Q1 2026, its #7466 holding.
JP Morgan Chase first reported a position in iBio in Q2 2020 and has held it in 24 quarters since.
JP Morgan Chase's iBio position peaked at $909K in Q1 2021.
52 funds tracked by Wall St. Rank held iBio as of Q1 2026.

Based on JP Morgan Chase's 13F filing for Q1 2026, filed 13 May 2026.